TENFU (06868) repurchased 2,000 shares for HKD 5,270 on September 18.
TENFU (06868) announced that on September 18, 2026, the company repurchased 2,000 shares for HKD 5,270.
TENFU (06868) announced that on September 18, 2026, the company repurchased 2,000 shares for HKD 5,270.
Related Articles
TRANSTHERA-B(02617): First Patient Dosed in China Phase II Clinical Trial of Tinengotinib Combined with Novel Endocrine Therapy for Metastatic Castration-Resistant Prostate Cancer After Progression on Prior Treatment
NAYUKI (02150) repurchased 487,000 shares for HK$355,400 on September 18.
IMPACT THERAP-B (07630): Senaparib receives positive CHMP opinion, expected to be used for first-line maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer
TRANSTHERA-B(02617): First Patient Dosed in China Phase II Clinical Trial of Tinengotinib Combined with Novel Endocrine Therapy for Metastatic Castration-Resistant Prostate Cancer After Progression on Prior Treatment
NAYUKI (02150) repurchased 487,000 shares for HK$355,400 on September 18.
IMPACT THERAP-B (07630): Senaparib receives positive CHMP opinion, expected to be used for first-line maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer
RECOMMEND
